iiinova — where your digital self keeps evolving

Reposted by Andrea Dimitracopoulos

Milner Therapeutics Institute 🧪 @milnerinst.bsky.social · 10/09/2026

🧬 10th Cambridge–UTokyo Joint Symposium Join Milner’s Namshik Han will be speaking at the Frontiers in Molecular & Cellular Biology Dialogue Sessions, bringing together researchers from Cambridge and Tokyo. 📅 25 Sept | ⏰ 09:00–12:00 📍 Dept of Pathology 🔗 ow.ly/Hlyx50ZIUSH

021

Reposted by Andrea Dimitracopoulos

susiemclaren.bsky.social @susiemclaren.bsky.social · 02/09/2026

Corals internalise algae into their cells to form a symbiosis that underpins reef ecosystems. How does the host integrate symbionts into its body plan? Happy to share our preprint: Symbiont spatial organisation is dynamically regulated within cnidarian host tissues. doi.org/10.64898/202...

A confocal microscopy image of a tentacle bud stage cnidarian polyp with symbionts embedded in its tissue. The polyp morphology is visualised with an actin stain and the symbionts are visualised with their segmentation masks.

263

Reposted by Andrea Dimitracopoulos

Greg Landrum @greglandrum.bsky.social · 18/08/2026

The #RDKit UGM in Darmstadt is almost here (16-18 September), but if you want to attend, we still have some slots available. Free registration here: www.eventbrite.com/e/15th-rdkit...

eventbrite.com

15th RDKit UGM 2026

2026 RDKit User Group Meeting (in person and online)

167

Reposted by Andrea Dimitracopoulos

Milner Therapeutics Institute 🧪 @milnerinst.bsky.social · 11/08/2026

📣 Psssst! We are looking for a Community Engagement Coordinator to join the Entrepreneurships C:HT team! 🔗 www.cam.ac.uk/jobs/community-engage…

011

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 09/07/2026

MMV and @deepmirror.bsky.social are advancing the next phase of Drug Design for Global Health (dd4gh), our open-access AI-powered drug discovery platform, with a new grant from the @gatesfoundation.bsky.social. Learn more: bit.ly/4beUFze

bit.ly

MMV and deepmirror continue partnership to advance AI tool for global health drug discovery | Medicines for Malaria Venture

012

Reposted by Andrea Dimitracopoulos

Buzz Baum @buzzbaum.bsky.social · 26/06/2026

Archaeaophiles! Last chance to sign up as a virtual attendee for MBoA2026. It’s cheap and you will have access to all the talks include our archaea@50 celebration with a special guest: meetings.embo.org/event/26-arc...

meetings.embo.org

Molecular Biology of Archaea: Life Through the Prism of Archaea

In 1977, Woese and colleagues revealed Archaea as a distinct domain of life. Building on this insight, the discovery of Asgard archaea has strengthened the view that many hallmarks of eukaryotic cell…

12618

Reposted by Andrea Dimitracopoulos

TRIMTECH Therapeutics @trimtechtx.bsky.social · 23/06/2026

Delighted to announce increasing our total seed round to $47M, with an additional $14M investment to support further development of our targeted protein degrader portfolio. Read more: shorturl.at/DfaXn

021

Reposted by Andrea Dimitracopoulos

TRIMTECH Therapeutics @trimtechtx.bsky.social · 22/06/2026

On Thursday 25 June, Andrea Testa and Dean Clift will be in Maine presenting at the Gordon Research Conference on Induced Proximity Modalities and Therapeutics. See below for more details ⬇️

011

Reposted by Andrea Dimitracopoulos

Gautam Dey @gautamdey.bsky.social · 09/06/2026

Science really takes a village. Thrilled to share this with my friend @dudinlab.bsky.social, and with our brilliant and fearless teams, our collaborators around the world and our mentors - in my case a special shoutout to Buzz Baum, Jan Ellenberg and @monicabettencourt.bsky.social. 1/2

1018826

Reposted by Andrea Dimitracopoulos

Liverpool School of Tropical Medicine @lstmnews.bsky.social · 05/06/2026

Three fully funded PhD opportunities available. Applicants from a range of academic backgrounds are encouraged to apply, but these opportunities are only available to applicants with Home fee status. Full details and how to apply: lstm.ac/studentships

021

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 16/05/2026

This week, MMV and @dndi.org drug discovery teams came together to exchange ideas, common challenges and lessons learned across our research. From prioritizing promising compounds to advancing research in endemic countries, shared learning helps strengthen global health #innovation.

072

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 15/05/2026

British science is behind 1 in 5 tools in the antimalarial R&D pipeline. Sustaining investment in UK malaria research could accelerate progress towards #malaria elimination while generating ripple effects across global health and economic development: bit.ly/49vc8T5

021

Reposted by Andrea Dimitracopoulos

Altmetric @altmetric.com · 15/05/2026

Wow, fully dropping the bird. Big move by @ec.europa.eu Publishers, where you at?

07720

Reposted by Andrea Dimitracopoulos

Neil Lawrence @lawrennd.bsky.social · 13/05/2026

My letter to the Financial Times was published today on centralised vs devolved AI deployment. www.ft.com/content/75eb...

ft.com

Letter: A mistake markets make when they value software groups

From Neil Lawrence, DeepMind Professor of Machine Learning, University of Cambridge; Chair, ai@cam, Cambridge, UK

1215

Reposted by Andrea Dimitracopoulos

OpenBind @openbind.bsky.social · 11/05/2026

Our latest blog takes a behind‑the‑scenes look at the experimental and structural biology work behind #OpenBind’s first data release - from protein production to crystallographic model building and refinement. loom.ly/Ydcti7A #StructuralBiology #Crystallography #OpenScience

032

Reposted by Andrea Dimitracopoulos

Milner Therapeutics Institute 🧪 @milnerinst.bsky.social · 08/05/2026

🚀 Join us for the annual Milner Pitch Day, taking place ahead of #MilnerSymp26 🗓️ 6 July ⏰ 3–6pm 📍 Jesus College, Cambridge & online This showcase highlights promising pre-Series A companies from the Milner bio-incubator, local accelerators and international partners. 🔗 ow.ly/kykx50YzF4J

011

Reposted by Andrea Dimitracopoulos

OpenBind @openbind.bsky.social · 08/05/2026

The latest blog from #OpenBind introduces a new structure–affinity dataset for the EV‑A71 2A protease, alongside reference benchmarks and guidance on how the community can use and evaluate it across docking, co‑folding, and affinity prediction. loom.ly/6xPIRUc #OpenScience #DrugDiscovery #AI

042

Reposted by Andrea Dimitracopoulos

TRIMTECH Therapeutics @trimtechtx.bsky.social · 08/05/2026

We’re delighted that TRIMTECH Therapeutics won 'Start-Up of the Year' at the 2026 Cambridge Independent Science & Technology Awards! Huge thanks to our team and supporters for helping drive our mission forward. Read more: lnkd.in/dJmmd_6S

011

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 06/05/2026

Funding opportunity for women researchers in sub-Saharan Africa. 2026 L’Oréal-UNESCO For Women in Science Programme: • PhD & postdoc (SSA) • 30 PhD + 8 postdoc grants • €10k / €15k + leadership training Deadline: 15 May 2026 Apply: bit.ly/4cXDgv6

011

Reposted by Andrea Dimitracopoulos

Liverpool School of Tropical Medicine @lstmnews.bsky.social · 06/05/2026

In the latest episode of the Guardian’s Science Weekly podcast, Professor Jonathan Ball speaks to Madeleine Finlay about suspected cases of hantavirus aboard a cruise ship travelling from Argentina to Cape Verde. Listen here: www.theguardian.com/science/audi...

theguardian.com

Hantavirus explained: how does it spread and who is most at risk? – podcast

Madeleine Finlay talks to Prof Jonathan Ball from Liverpool School of Tropical Medicine to find out more about the virus behind the outbreak on a luxury cruise ship

021

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 06/05/2026

At #RNPM26 in Brazil, MMV marked #WorldMalariaDay by discussing advances in tackling relapsing vivax #malaria. Brazil’s rollout of new tools like single-dose tafenoquine is helping redefine what’s possible for elimination.

011

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 05/05/2026

We are deeply saddened by the passing of Dame Bridget Ogilvie, founding Chair of MMV. Her leadership helped establish MMV’s collaborative model & laid the foundation for a pipeline of antimalarials when they were needed most. Our thoughts are with her family and colleagues: bit.ly/3OVSJ70

bit.ly

In memory of Dame Bridget Ogilvie: Founding Chair of Medicines for Malaria Venture | Medicines for Malaria Venture

022

Reposted by Andrea Dimitracopoulos

Open Source for Science Fund @os4science.org · 04/05/2026

Today we're launching the Open Source for Science Fund, a new multi-donor philanthropic fund by Renaissance Philanthropy, seeded by @biohub.org and @wellcometrust.bsky.social, with support from @kavlifoundation.org and @researchsoftware.bsky.social 🧵 os4science.org/news/open-so...

os4science.org

Open Source for Science Fund Launches to Power AI-Driven Discovery

A new multi-donor fund by Renaissance Philanthropy seeded by Biohub and Wellcome opens its first call for proposals.

13515

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 30/04/2026

How are partnerships strengthening R&D capacity in Africa & what does this mean for #malaria? At a #WHSNairobi2026 side event, MMV & partners highlighted initiatives like RAFIKI, which is strengthening R&D in endemic countries while fostering new Africa/Europe collaborations. #WorldMalariaDay

021

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 28/04/2026

United in the fight against #malaria and staying one step ahead of antimalarial drug resistance. Building on the momentum of #WorldMalariaDay, yesterday MMV and the RBM Partnership to End Malaria convened partners in Geneva to align and strengthen our collective response to drug resistance.

141

Reposted by Andrea Dimitracopoulos

Drug Discovery Unit, University of Dundee @ddu-dundee.bsky.social · 25/04/2026

"Since 2010, the DDU malaria team, working with academic and industry partners, has been dedicated to discovering new medicines to treat and prevent malaria. One major success has been the discovery of Cabamiquine (DDD498)..." #NowWeCanNowWeMust #WorldMalariaDay #Research #EndMalaria #DDUAT20

232

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 25/04/2026

We can end malaria in our lifetime. New tools like single-dose cures & long-acting injectables are coming, while countries scale up #vaccines & next-gen nets. But #malaria doesn’t wait. When funding drops, it resurges. Protect progress. Invest in what comes next. #WMD2026

021

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 25/04/2026

British-backed science has helped build today’s antimalarial toolbox. Sustained support can get us closer to #ZeroMalaria. UK Parliamentarians explored tools behind progress against #malaria and innovations that can define what’s next at @malarianomoreuk.bsky.social #WorldMalariaDay event.

043

Reposted by Andrea Dimitracopoulos

Drug Discovery Unit, University of Dundee @ddu-dundee.bsky.social · 25/04/2026

Children under five and pregnant women are the most at risk from malaria, accounting for the majority of the approximately 600,000 deaths each year worldwide. #NowWeCanNowWeMust #WorldMalariaDay #EndMalaria #GlobalHealth #HealthEquity #DrugDiscovery #InfectiousDiseases #PublicHealth #DDUAT20

133

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 23/04/2026

🤍 White for health 💚 Green for prevention and awareness A small group in Geneva, part of a global team marking #WorldMalariaDay. We know this fight can be won through #partnership, #innovation and determination. #ZeroMalaria

121

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 22/04/2026

#Malaria is preventable and treatable, yet it still takes lives every day. MMV-supported medicines have reached over 1 billion people since 1999. But the fight is changing. Drug resistance, climate pressure and funding challenges are putting progress at risk. #WorldMalariaDay

031

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 21/04/2026

“It’s time we have the first approved and accessible African-invented antimalarial,” said MMV CEO Martin Fitchet at last year's @worldhealthsummit.bsky.social. With dd4gh, this ambition can start taking shape, expanding who gets to contribute to drug discovery 👉 bit.ly/4mdsWmI

011

Reposted by Andrea Dimitracopoulos

Buzz Baum @buzzbaum.bsky.social · 21/04/2026

bbc.com/audio/brand/... Now free for all archaea lovers to hear!

bbc.com

BBC Audio | In Our Time

Listen to the latest episodes of In Our Time on BBC Audio

04711

Reposted by Andrea Dimitracopoulos

TRIMTECH Therapeutics @trimtechtx.bsky.social · 21/04/2026

Our CEO Nicki Thompson will be joining the "Partnering with Big Pharma" panel at AngloNordic Life Science Conference XXII in London on Thursday. Reach out if you’d like to meet 📩 trimtechtherapeutics.com/contact/

011

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 21/04/2026

How can we get #malaria elimination back on track as drug resistance rises? During a @who.int Regional Office for Africa webinar today, MMV's André-Marie Tchouatieu joined partners to highlight next-generation tools designed to stay ahead of resistance & improve treatment adherence. #WMD26

121

Reposted by Andrea Dimitracopoulos

Milner Therapeutics Institute 🧪 @milnerinst.bsky.social · 15/04/2026

Is there a secret to getting 10 drugs approved? 🤔💊 Join the Founders Growth Community as they welcome Christoph Lengauer (Curie.Bio), sharing insights on bringing drugs to market and building in life sciences. 🗓️ Tomorrow, 3.30pm 📍 Deloitte, Cambridge 🔗 ow.ly/5br250YyHhX

011

Reposted by Andrea Dimitracopoulos

ai@cam @ai.cam.ac.uk · 14/04/2026

Tune in to hear @lawrennd.bsky.social, Chair of ai@cam, contribute to the House of Commons Business and Trade Committee inquiry on #ArtificialIntelligence, #business and the future of the workforce. ➡️ Watch live from 14.30! parliamentlive.tv/event/index/...

parliamentlive.tv

Parliamentlive.tv

Business and Trade Committee

033

Reposted by Andrea Dimitracopoulos

Drug Discovery Unit, University of Dundee @ddu-dundee.bsky.social · 14/04/2026

Because in diseases like Chagas, leaving even a single parasite behind isn’t an option. At DDU, we developed a washout assay to determine if compounds can achieve complete parasite clearance. #DrugDiscovery #NTD #ChagasDisease #GlobalHealth #ScientificInnovation #NeglectedDiseases #Research

An image of intracellular parasites that have been labelled so they are visible.

032

Andrea Dimitracopoulos @andrea.dimitracopoulos.me · 10/04/2026

I am excited to be speaking at #BioTrinity2026 next Tuesday in London at the Wellcome Genome Campus showcase, focused on how biodata ventures are shaping the future of life sciences. I'll be sharing how we are tackling the data bottleneck in AI-driven drug discovery at @deepmirror.bsky.social

100

Reposted by Andrea Dimitracopoulos

Liverpool School of Tropical Medicine @lstmnews.bsky.social · 09/04/2026

Different chemical coatings used on mosquito nets can affect how well they perform, which means that nets should be assessed on more than just their insecticide content alone, new research shows. Read more: lstmed.ac.uk/news/chemica...

lstmed.ac.uk

Chemical coatings can change mosquito net performance, highlighting need for broader evaluation | Liverpool School of Tropical Medicine

9 April 2026

022

Reposted by Andrea Dimitracopoulos

Buzz Baum @buzzbaum.bsky.social · 09/04/2026

🧬 Last call to join us in Cambridge for #EMBOMBoA26 (July 6th-10th)! We are just one week away from the registration and abstract submission deadline for the EMBO Workshop on the Molecular Biology of Archaea!

42116

Andrea Dimitracopoulos @andrea.dimitracopoulos.me · 31/03/2026

After a year of co-creation with dozens of amazing global health researchers, we are thrilled to launch #dd4gh (Drug Design for Global Health) at @deepmirror.bsky.social, in partnership with Medicines for Malaria Venture @mmv.org. Learn more in the thread below, and apply for access here: dd4gh.ai

dd4gh.ai

dd4gh - Drug Design for Global Health

dd4gh is a free, open-access AI platform by Medicines for Malaria Venture and deepmirror that helps researchers design and prioritise drug candidates for global health challenges.

120

Reposted by Andrea Dimitracopoulos

Medicines for Malaria Venture (MMV) @mmv.org · 31/03/2026

MMV & @deepmirror.bsky.social have launched dd4gh, an open-access AI platform giving researchers in LMICs access to advanced drug discovery tools. Designed to reduce costs & timelines, dd4gh is levelling the playing field for all scientists shaping research into #malaria & other diseases.

133

Reposted by Andrea Dimitracopoulos

Liverpool School of Tropical Medicine @lstmnews.bsky.social · 30/03/2026

Researchers at Liverpool School of Tropical Medicine have identified a bacterium linked to noma, a devastating disease that affects young children. The discovery could enable earlier diagnosis and treatment, when it matters most. Read more: lstm.ac/4bId3RO

141

Reposted by Andrea Dimitracopoulos

RSC-CICAG @rsc-cicag.bsky.social · 30/03/2026

Contribution from Dr Ryan Greenhalgh, CTO and Dr Tushar Modi, Research Scientist. TLDR Cofolding models are only as strong as their data and securely shared protein–ligand datasets are now the bottleneck to use in drug-discovery programs. Read the full article: www.rsccicag.org/index_htm_fi...

rsccicag.org

031

Reposted by Andrea Dimitracopoulos

Greg Landrum @greglandrum.bsky.social · 27/03/2026

Free registration for the 2026 #RDKit UGM (both in-person and online attendance) is now open: www.eventbrite.com/e/1985889262...

eventbrite.com

15th RDKit UGM 2026

2026 RDKit User Group Meeting (in person and online)

0109